Ausdal Financial Partners, Inc. Amarin Corp Plcuk Transaction History

Ausdal Financial Partners, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$1.09 - $1.67 $11,445 - $17,535	10,500 New	10,500 $11,000
Q4 2021 Feb 08, 2022	SELL	$3.24 - $5.18 $41,472 - $66,304	-12,800 Closed	0 $0
Q2 2021 Jul 19, 2021	SELL	$4.26 - $6.5 $11,493 - $17,537	-2,698 Reduced 17.41%	12,800 $56,000
Q1 2021 May 05, 2021	BUY	$5.03 - $8.8 $503 - $880	100 Added 0.65%	15,498 $90,000
Q4 2020 Feb 01, 2021	SELL	$4.04 - $5.31 $15,756 - $20,709	-3,900 Reduced 20.21%	15,398 $69,000
Q3 2020 Nov 04, 2020	BUY	$3.64 - $7.76 $19,284 - $41,112	5,298 Added 37.84%	19,298 $75,000
Q2 2020 Aug 06, 2020	BUY	$4.78 - $8.26 $9,560 - $16,520	2,000 Added 16.67%	14,000 $97,000
Q1 2020 May 04, 2020	BUY	$4.0 - $21.53 $1,800 - $9,688	450 Added 3.9%	12,000 $81,000
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $20,910 - $36,180	1,500 Added 14.93%	11,550 $223,000
Q3 2019 Nov 19, 2019	BUY	$13.89 - $23.16 $139,594 - $232,758	10,050 New	10,050 $152,000

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $177M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.